A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #235

Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.

Danila GM, Puiu M, Zamfir LG, et al. Talanta. 2022.
Weak / noneIn vitroMentions: CJC-1295

Editor's note

This in-vitro study is really about cannabinoids, with CJC-1295 appearing only as a reference compound. The researchers report that cannabidiol (CBD) and a THC metabolite bind the growth-hormone-secretagogue receptor (GHS-R1a) and, unusually, promote ghrelin binding to it, behaving differently from synthetic ghrelin mimetics such as CJC-1295, which acted as competitive inhibitors in their assay. They used these differing affinity profiles to build a urine-screening approach for the cannabinoids. For readers interested in CJC-1295, the relevance is minimal and indirect: it serves as a known comparator ligand, and the study says nothing about its clinical effects, dosing, or safety. Worth noting that CJC-1295 is more usually described as a GHRH analogue, so its labelling here as a ghrelin mimetic is a loose characterisation. This is a cell and receptor-level analytical study; no human or clinical conclusions about CJC-1295 follow from it.

Plain-language abstract

This laboratory study is mainly about detecting cannabis compounds, using the peptide CJC-1295 only as a comparison substance. The researchers studied how different molecules bind to a receptor called GHS-R1a, the natural target of the hunger hormone ghrelin. They found, for the first time, that CBD (cannabidiol) and a breakdown product of THC attach to this receptor and actually strengthen ghrelin's binding to it. This behaviour was clearly different from synthetic ghrelin-mimicking substances such as CJC-1295, which instead competed with and blocked ghrelin in their test. Because the binding patterns differ, the researchers were able to design a urine test that detects the cannabis compounds without interference from substances like CJC-1295. They validated the test against an established reference method. The study is about detecting cannabinoids in urine; it does not examine what CJC-1295 does in the body or whether it is safe or effective.